Ultragenyx Gains Worldwide Rights for Triheptanoin (UX007)
Option Exercised for Ex-North American Territories
Novato, CA –July 11, 2013–Ultragenyx announced that it has expanded its exclusive license from Baylor Research Institute (BRI)in Dallas, Texas,to develop and commercialize triheptanoin outside of North America. The global license includes rights to patents, patent applications and other intellectual property related to the composition and formulation of UX007 as well as its use in treating a number of diseases including fatty acid oxidation disorders (FAOD), the lead indication being developed by the company.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.